Andrew Huberman joins Hims & Hers board as YouTube tops 8 million

Stanford neuroscientist Andrew Huberman will join Hims & Hers' board as the Huberman Lab YouTube channel exceeds 8 million subscribers, giving him a direct role at a telehealth company with nearly 3 million customers.

Huberman built his audience by translating science into practical guidance on sleep, fitness, hormones, supplements and longevity. His podcast regularly ranks among the most popular in health and science. The YouTube channel and podcast reach millions of health-conscious listeners each month.

The appointment creates three connected roles:

• Board: Huberman will join former Netflix CFO David Wells and former DoorDash CFO Kofi Amoo-Gottfried.
• Advice: He will formally advise Hims on science and brand marketing.
• Media: He will provide separate marketing support through the Huberman Lab podcast. Scicomm Media, his media company, will run Hims advertisements and receive payment.

Hims has expanded from hair loss and erectile dysfunction into weight loss, testosterone, preventive care and peptides. The company can sell many of the treatments Huberman discusses. The arrangement also puts his name behind Hims' expanding menu of care and gives him a role in its strategy.

His editorial promise is specific: “We will never filter information differently because of a brand relationship,” Huberman said.

He said his content will continue to address benefits, risks and uncertainty. Hims also encouraged him to educate audiences independently of any product or platform. Huberman and CEO Andrew Dudum said he will remain free to cover the category broadly.

What does this change for Hims and its customers?

For Hims, the appointment adds scientific credibility, branded reach and a podcast advertising channel. For customers, it brings more access to personalized care, alongside a new conflict test.

For Huberman, the board seat turns outside advice into a fiduciary and strategic role. He had advised fitness and sleep brands before, but this arrangement gives him firsthand involvement in company decisions. He first contacted Dudum through a mutual friend, then spent six to eight months discussing the future of consumer healthcare.

“Joining the board allows me to do that rather than just only talk about how Hims & Hers can do that,” he said, referring to their shared goal of bringing the best healthcare practices to the broadest number of people.

On a joint Monday call, both men described the same goal: make personalized healthcare more accessible. Dudum framed it as empowering people worldwide to feel better and take more agency in their lives.

Huberman sees Hims filling the gap between traditional care, where patients can struggle to get time and attention, and high-end concierge care. He said the “middle 95%” should be able to access personalized care.

Hims is not alone. Ro, Midi, longevity clinics, testing startups and consumer-health brands are trying to turn once-niche services into mainstream offerings. Hims enters that contest with nearly 3 million customers, its own pharmacy and manufacturing infrastructure, and a podcaster whose audience reaches millions each month.

His appointment matters most as Hims pushes into testosterone and peptides, a category that has shifted from niche biohacking obsession to mainstream interest in recent months. Huberman has become a prominent public voice on injectable peptides, while Dudum has built Hims to sell them.

The company's peptide plans predate the board appointment and a recent HHS move that temporarily made some popular peptides available by prescription. Hims signed a deal for a California peptide facility at the end of 2024 and announced the acquisition in February 2025.

By May, Dudum told investors the company was following peptide innovation deeply. He cited potential uses in pain management, recovery and generalized longevity.

In recent weeks, Hims previewed Peptides+, a website section that will offer various peptides once regulatory approval permits, including BPC-157. It will also feature other wellness therapies such as NAD+ and vitamin B12.

Huberman said he has no interest in broad peptide use among people who do not need them. He added that he does not know whether someone without an injury needs BPC-157 or TB-500.

A major reason for joining the board was Hims' plan to control peptide manufacturing from start to finish. He also wants the company to lead the discussion of what peptides can and cannot do, calling Hims a channel for information rather than a barrier. Dudum said personalized health and longevity require extreme care and caution.

Commercial alignment creates a test for consumers and advertisers. Huberman did not specify how individual podcast episodes, social posts or short clips will disclose his board seat and separate marketing relationship. The paid Hims ads through Scicomm make the tie commercial as well as editorial.

The bet is that Hims can offer a more rigorous route through a flood of wellness claims. Huberman believes the service can turn customers into scientists of their own health. The unresolved issue is whether that rigor survives when the expert directing the conversation also sits in the boardroom and helps market the company's services.

For customers, the change offers a high-profile science adviser and easier access to personalized care, but only if disclosures make the commercial influence clear. For Hims, the appointment adds reach and credibility. It also requires the company to turn its promise of editorial independence into operating practice.